Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Diseases | 2 | 2022 | 172 | 1.240 |
Why?
|
| Drug Delivery Systems | 9 | 2019 | 182 | 0.920 |
Why?
|
| Nanoparticles | 3 | 2022 | 231 | 0.850 |
Why?
|
| Tissue Scaffolds | 2 | 2020 | 73 | 0.840 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 4 | 2018 | 25 | 0.790 |
Why?
|
| Printing, Three-Dimensional | 2 | 2020 | 68 | 0.720 |
Why?
|
| Ophthalmic Solutions | 2 | 2019 | 89 | 0.670 |
Why?
|
| Posterior Eye Segment | 1 | 2019 | 3 | 0.660 |
Why?
|
| Eye | 2 | 2017 | 227 | 0.600 |
Why?
|
| Biocompatible Materials | 3 | 2020 | 123 | 0.450 |
Why?
|
| Inflammation | 1 | 2020 | 1401 | 0.440 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 15 | 0.430 |
Why?
|
| Spheroids, Cellular | 1 | 2013 | 58 | 0.420 |
Why?
|
| Polymers | 4 | 2020 | 106 | 0.410 |
Why?
|
| Dexamethasone | 3 | 2017 | 272 | 0.350 |
Why?
|
| Polyvinyl Alcohol | 2 | 2020 | 10 | 0.320 |
Why?
|
| Cornea | 5 | 2017 | 645 | 0.320 |
Why?
|
| Delayed-Action Preparations | 3 | 2019 | 110 | 0.320 |
Why?
|
| Caspase 2 | 1 | 2024 | 26 | 0.230 |
Why?
|
| Animals | 12 | 2024 | 33759 | 0.220 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1661 | 0.220 |
Why?
|
| Nanotechnology | 2 | 2015 | 48 | 0.200 |
Why?
|
| Dry Eye Syndromes | 2 | 2016 | 247 | 0.200 |
Why?
|
| Neoplasms | 2 | 2014 | 2758 | 0.190 |
Why?
|
| CD4 Antigens | 1 | 2021 | 55 | 0.190 |
Why?
|
| Platelet Factor 4 | 1 | 2021 | 22 | 0.190 |
Why?
|
| CD8 Antigens | 1 | 2021 | 40 | 0.180 |
Why?
|
| Bioprinting | 1 | 2020 | 9 | 0.180 |
Why?
|
| Mice | 8 | 2024 | 17503 | 0.180 |
Why?
|
| Hernia, Ventral | 1 | 2020 | 40 | 0.180 |
Why?
|
| Microtechnology | 2 | 2011 | 6 | 0.180 |
Why?
|
| Herniorrhaphy | 1 | 2020 | 80 | 0.170 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 477 | 0.170 |
Why?
|
| Retina | 1 | 2022 | 456 | 0.160 |
Why?
|
| Particle Size | 4 | 2014 | 116 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2019 | 143 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 532 | 0.160 |
Why?
|
| Leydig Cells | 1 | 2018 | 20 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 394 | 0.150 |
Why?
|
| Polyesters | 1 | 2018 | 40 | 0.150 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 1265 | 0.150 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 3274 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 1213 | 0.140 |
Why?
|
| Apoptosis | 1 | 2024 | 1781 | 0.140 |
Why?
|
| Nanostructures | 3 | 2016 | 52 | 0.140 |
Why?
|
| Oxidative Stress | 1 | 2022 | 795 | 0.140 |
Why?
|
| Cytokines | 2 | 2020 | 1285 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2024 | 2307 | 0.140 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2017 | 12 | 0.140 |
Why?
|
| Cysteamine | 1 | 2016 | 14 | 0.140 |
Why?
|
| Cystinosis | 1 | 2016 | 15 | 0.140 |
Why?
|
| Eye Burns | 1 | 2016 | 15 | 0.130 |
Why?
|
| Polyglycolic Acid | 3 | 2011 | 27 | 0.130 |
Why?
|
| Burns, Chemical | 1 | 2016 | 29 | 0.130 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2015 | 12 | 0.130 |
Why?
|
| Lactic Acid | 3 | 2011 | 146 | 0.120 |
Why?
|
| Rats | 1 | 2020 | 3653 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 280 | 0.110 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2013 | 153 | 0.100 |
Why?
|
| Hydrogels | 2 | 2010 | 77 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1591 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 530 | 0.090 |
Why?
|
| Mutation | 1 | 2024 | 5773 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2010 | 98 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2010 | 80 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2478 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 4 | 2016 | 4353 | 0.070 |
Why?
|
| Cell Self Renewal | 1 | 2024 | 41 | 0.060 |
Why?
|
| Humans | 6 | 2024 | 123224 | 0.050 |
Why?
|
| Transplantation, Isogeneic | 1 | 2021 | 15 | 0.050 |
Why?
|
| DNA Damage | 1 | 2024 | 505 | 0.050 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 126 | 0.050 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 48 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 70 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2018 | 3042 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 285 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 695 | 0.040 |
Why?
|
| Cells, Immobilized | 1 | 2018 | 7 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 877 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2018 | 87 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1472 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2018 | 173 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2018 | 211 | 0.030 |
Why?
|
| Cystine | 1 | 2016 | 15 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1907 | 0.030 |
Why?
|
| Alkalies | 1 | 2016 | 24 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2018 | 176 | 0.030 |
Why?
|
| Female | 6 | 2021 | 65550 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 806 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 326 | 0.030 |
Why?
|
| Drug Liberation | 1 | 2015 | 11 | 0.030 |
Why?
|
| Indazoles | 1 | 2015 | 23 | 0.030 |
Why?
|
| Diffusion | 1 | 2015 | 58 | 0.030 |
Why?
|
| Corneal Neovascularization | 1 | 2015 | 12 | 0.030 |
Why?
|
| Extracellular Fluid | 1 | 2014 | 12 | 0.030 |
Why?
|
| Microfluidics | 1 | 2014 | 18 | 0.030 |
Why?
|
| Capillaries | 1 | 2014 | 66 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 133 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 221 | 0.030 |
Why?
|
| Imidazoles | 1 | 2015 | 199 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2016 | 378 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 231 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2014 | 635 | 0.020 |
Why?
|
| Wound Healing | 1 | 2015 | 452 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2014 | 527 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 523 | 0.020 |
Why?
|
| Silicon | 1 | 2009 | 12 | 0.020 |
Why?
|
| Gelatin | 1 | 2009 | 15 | 0.020 |
Why?
|
| Phase Transition | 1 | 2009 | 17 | 0.020 |
Why?
|
| Materials Testing | 1 | 2009 | 73 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2009 | 391 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 601 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 1313 | 0.020 |
Why?
|
| Swine | 1 | 2009 | 1155 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 4273 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 12141 | 0.010 |
Why?
|
| Male | 1 | 2018 | 60118 | 0.010 |
Why?
|